Search results for "Cut"

showing 10 items of 5063 documents

Oral lichen planus and its relationship with systemic diseases. A review of evidence

2018

Background Oral lichen planus (OLP) is one of the most common dermatological diseases which are present in the oral cavity. It is a chronic autoimmune, mucocutaneous disease that affects the oral mucosa as well as the skin, genital mucosa and other sites. Objective Review the relevant information to OLP and its relationship with systemic diseases. Material and Methods Searches were carried out in the Medline/PubMed, Lilacs, Bireme, BVS, and SciELO databases by using key-words. After an initial search that provided us with 243 papers, this number was reduced to 78 from the last seven years. One of the first criteria adopted was a selective reading of the abstracts of articles for the elimina…

medicine.medical_specialtyEtiologyMucocutaneous zoneMEDLINELiquen plaDiseaseReviewMucosa oral030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinestomatognathic systemmedicineOral mucosaGeneral Dentistrybusiness.industry030206 dentistryEvidence-based medicinemedicine.disease:CIENCIAS MÉDICAS [UNESCO]DermatologyClinical trialSkin diseasesstomatognathic diseasesmedicine.anatomical_structureMalalties de la pellEtiologiaUNESCO::CIENCIAS MÉDICASOral lichen planusOdontostomatology for the Disabled or Special PatientsOral mucosabusinessLichen planusCohort study
researchProduct

Safety and efficacy of biodegradable polymer-coated thin strut sirolimus-eluting stent vs. durable polymer-coated everolimus-eluting stent in patient…

2018

Introduction The biodegradable polymer drug-eluting stents were developed to improve vascular healing. However, further data are needed to confirm the safety and efficacy of these stents in patients with acute myocardial infarction (AMI). Aim We sought to determine the 1-year clinical follow-up in patients with AMI treated with a thin strut biodegradable polymer-coated sirolimus-eluting stent (BP-SES) versus a durable coating everolimus-eluting stent (DP-EES). Material and methods We analyzed patients with AMI (STEMI and NSTEMI) treated with either a BP-SES (ALEX, Balton, Poland, n = 886) or DP-EES (XIENCE, Abbott, USA, n = 1054) with available 1-year clinical follow-up using propensity sco…

medicine.medical_specialtyEverolimus eluting stentmedicine.medical_treatmentacute myocardial infarctionlcsh:Medicine030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinemedicineIn patientcardiovascular diseases030212 general & internal medicineMyocardial infarctionOriginal Paperbusiness.industrylcsh:Rdrug-eluting stentsStentPercutaneous coronary interventionequipment and suppliesmedicine.diseaseBiodegradable polymerSurgerybioabsorbable polymerSirolimusPropensity score matchingCardiology and Cardiovascular Medicinebusinessmedicine.drugAdvances in Interventional Cardiology
researchProduct

1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents

2016

Abstract Objectives The purpose of this study was to compare the 1-year outcomes of the ABSORB everolimus-eluting bioresorbable scaffold (BRS) (Abbott Vascular, Santa Clara, California) and the XIENCE everolimus-eluting stent (EES) (Abbott Vascular) in patients undergoing percutaneous coronary intervention. Background Randomized studies of the ABSORB BRS have been performed in selected patient and lesion scenarios. The available registries of the ABSORB BRS reflect real-world practice more closely compared with randomized studies, but most of them are limited by the small sample size and the lack of comparative outcomes versus second-generation drug-eluting stents. Methods A total of 1,189 …

medicine.medical_specialtyEverolimusbusiness.industrymedicine.medical_treatmentPercutaneous coronary interventionStent030204 cardiovascular system & hematologymedicine.diseaseConfidence interval03 medical and health sciences0302 clinical medicineInternal medicinePropensity score matchingConventional PCIClinical endpointmedicineCardiology030212 general & internal medicineMyocardial infarctionCardiology and Cardiovascular Medicinebusinessmedicine.drugJACC: Cardiovascular Interventions
researchProduct

P798Outcome of percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in patients with STEMI as compared to stab…

2018

medicine.medical_specialtyEverolimusbusiness.industrymedicine.medical_treatmentPercutaneous coronary interventionlanguage.human_languageGermanInternal medicineStable cadCardiologylanguageMedicineIn patientCardiology and Cardiovascular Medicinebusinessmedicine.drugEuropean Heart Journal
researchProduct

TCT-441 Optical Coherence Tomography assessment of the implantation of Everolimus-Eluting Bioresorbable Scaffolds against angiographic assessment: th…

2016

Bioresorbable Vascular Scaffolds (BVS) are the newest generation of stents for use during Percutaneous Coronary Intervention. However, as history has demonstrated, each development in stent technology has been associated with its own specific complications. With BVS, there are reports that recoil is

medicine.medical_specialtyEverolimusmedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentPercutaneous coronary interventionStentequipment and suppliessurgical procedures operativeOptical coherence tomographymedicinecardiovascular diseasesRadiologyCardiology and Cardiovascular MedicinebusinessBioresorbable scaffoldmedicine.drugJournal of the American College of Cardiology
researchProduct

European evidence based consensus for endoscopy in inflammatory bowel disease.

2013

Endoscopy plays an essential role in the diagnosis, management, prognosis, and surveillance of inflammatory bowel disease (IBD), but surprisingly there are few available guidelines.1,2 This prompted the ECCO Guidelines Committee (GuiCom) members to promote a Consensus on the appropriate indication and application of different endoscopic modalities in IBD. Since the development of guidelines is an expensive and time-consuming process, this Consensus may help to avoid duplication of effort in the future. It may also identify issues where the evidence is lacking and controlled studies are awaited. The strategy to reach the Consensus involved five steps: 1. Two members of the GuiCom (VA and RE)…

medicine.medical_specialtyEvidence-based practiceColonBiopsyIBDMEDLINEColonic PouchesInflammatory bowel diseaseSeverity of Illness IndexEndoscopy GastrointestinalCrohn's disease (CD)Diagnosis DifferentialColorectal cancer (CRC)IleumMedicineHumansUlcerative colitis (UC)computer.programming_languageModalitiesmedicine.diagnostic_testbusiness.industrydigestive oral and skin physiologyGastroenterologyRectumEndoscopyGeneral MedicineGuidelinemedicine.diseaseInflammatory Bowel Diseasesdigestive system diseasesSurgeryEndoscopyFamily medicinePopulation SurveillanceAcute DiseaseCONSENSUSbusinessWorking groupColorectal NeoplasmscomputerDelphiJournal of Crohn'scolitis
researchProduct

COVID‐19 and exacerbation of dermatological diseases: A review of the available literature

2021

Abstract Since the emergence of the new coronavirus disease 19 (COVID‐19) pandemic, there has been a concern for the patients with chronic autoimmune diseases including dermatological conditions over the potential exacerbation of these underlying conditions after infection with severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV2). We performed a systematic review to evaluate presentations, postinfection change in the manifestation, diagnosis, and management of flare‐ups of underlying dermatologic disease in patients with COVID‐19. A total of 17 articles were recovered reporting on flare‐ups of dermatological disease including pemphigus vulgaris, psoriasis, subacute cutaneous lupus er…

medicine.medical_specialtyExacerbationShort ReportDiseaseSclerodermaSubacute cutaneous lupus erythematosusexacerbationShort ReportsCOVID‐19PsoriasismedicineHumansflare‐upworseningskin and connective tissue diseasesPandemicsSARS‐Cov2business.industrySARS-CoV-2Pemphigus vulgarispemphigusCOVID-19General MedicinepsoriasisAlopecia areatamedicine.diseaseDermatologydermatologyPemphigusRNA ViralbusinessDermatologic Therapy
researchProduct

Predictive factors of severity and persistence of oropharyngeal dysphagia in sub-acute stroke.

2020

Purpose: This study aims to understand the factors contributing to the severity of oropharyngeal dysphagia and its persistence in the sub-acute phase of stroke. Methods: We retrospectively collected the data of all the patients suffering from a stroke in the last year. The severity of stroke was reported according to the NIHSS score. All the patients were evaluated with the Dysphagia Risk Score and with a FEES. We classified the Dysphagia Risk Score and FEES results using the PAS score and ASHA-NOMS levels. The data were analysed statistically with ANOVA test, Student’s t test and Pearson’s correlation coefficient. Results: A series of 54 patients were evaluated. The ANOVA test did not find…

medicine.medical_specialtyFEESSub acuteSeverity of Illness IndexPersistence (computer science)Nasogastric tube03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineMedicineHumanscardiovascular diseases030223 otorhinolaryngologyStrokeRetrospective StudiesFramingham Risk Scorebusiness.industryDysphagiaGeneral Medicinemedicine.diseaseDysphagiaStrokeAspirationOtorhinolaryngologyOtorhinolaryngology030220 oncology & carcinogenesisPredictor factorsNeurosurgerymedicine.symptombusinessDeglutition DisordersOropharyngeal dysphagiaEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
researchProduct

COVID-19 and oral lesions, short communication and review

2021

Background The COVID-19 disease first appeared in December 2019 in Wuhan, China. The World Health Organization (WHO) declared the pandemic in March 2020, with 40 million cases and a million deaths in October 2020. COVID-19 also includes manifestations on the skin and mucous mucosal membrane. Objective: To evaluate the prevalence of the oral lesions associated to COVID-19 disease; and evaluate their clinical presentation and the hypothesized etiology. Material and methods An electronic literature search was performed in PubMed, Scopus and Indice Medico Espanol databases. The following combination of keywords and Boolean operators were used: "COVID-19 AND oral manifestations"; "COVID-19 AND o…

medicine.medical_specialtyFerides i lesionsCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MEDLINEReviewDiseaseWorld healthMucosa oral03 medical and health sciences0302 clinical medicineTonguemedicineGeneral DentistryUNESCO:CIENCIAS MÉDICASOral Medicine and PathologySARS-CoV-2business.industryWounds and injuriesCOVID-19030206 dentistryEvidence-based medicineDermatologymedicine.anatomical_structure030220 oncology & carcinogenesisEtiologyOral mucosabusiness
researchProduct

Nephro-broncho-cutaneous Fistula

1989

medicine.medical_specialtyFistulaUrinary Fistulabusiness.industryUrologyCutaneous fistulaSkin DiseasesDermatologyRadiographyHumansMedicineFemaleKidney DiseasesBronchial FistulabusinessAgedBritish Journal of Urology
researchProduct